Resolvin D5 (RvD5), 7S,17S-dihydroxy-4Z,8E,10Z,13Z,15E,19Z-docosahexaenoic acid (DHA) is a specialized pro-resolving mediator (SPM) generated in human macrophages. It is implicated in the resolution of inflammation and synthesized using an inefficient chemical process. Here, DHA-enriched oil hydrolysate was prepared from oils by lipase with resin treatment and solvent extraction. The reaction factors on the biotransformation of oil hydrolysate into RvD5 were optimized using Escherichia coli expressing arachidonate double-oxygenating 15S-lipoxygenase. After optimization, the cells converted 5.0 mM (1.64 g/L) DHA in oil hydrolysate into 4.0 mM (1.44 g/L) RvD5 in a bioreactor for 3.0 h, which was 15-fold higher than that in a flask before optimization, and RvD5 with a purity of > 97% was prepared from reaction solution by treatments of resins. This is the first trial for the production of C22-dihydroxy fatty acid using a bioreactor. This study will contribute to the large-scale production of SPMs from oils.

Resolvin D5 (RvD5), 7 S ,17 S -二羟基-4 Z ,8 E , 10 Z ,13 Z ,15 E ,19 Z -二十二碳六烯酸 (DHA) 是一种在人体中产生的特殊促溶解介质 (SPM)巨噬细胞。它与炎症的消退有关，并且是使用低效的化学过程合成的。这里，富含 DHA 的油水解产物是通过脂肪酶通过树脂处理和溶剂萃取从油中制备的。使用表达花生四烯酸双加氧15S-脂加氧酶的大肠杆菌优化油水解产物生物转化为RvD5的反应因素。优化后，细胞在生物反应器中反应3.0 h，将油水解液中的5.0 mM（1.64 g/L）DHA转化为4.0 mM（1.44 g/L）RvD5，比优化前烧瓶中的转化量高15倍，并且由反应液经树脂处理制备纯度> 97%的RvD5。这是利用生物反应器生产C22-二羟基脂肪酸的首次试验。这项研究将有助于从油中大规模生产 SPM。